Device type · JPK
Mixture, Hematology Quality Control
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
JPK
Hematology
Device class
Class II
FDA decisions since 2015
4
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Mixture, Hematology Quality Control
- Product code
- JPK
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.8625
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for JPK
Latest FDA decisions
- XN-L CHECK510(k)
K160586 · Decided Dec 22, 2016 · 296 days after receipt
Device type: Mixture, Hematology Quality Control (JPK) · Laboratory Medicine & Pathology
- XN CHECK BF510(k)
K160588 · Decided Dec 22, 2016 · 296 days after receipt
Device type: Mixture, Hematology Quality Control (JPK) · Laboratory Medicine & Pathology
- XN CHECK510(k)
K160590 · Decided Dec 22, 2016 · 296 days after receipt
Device type: Mixture, Hematology Quality Control (JPK) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0999-2023 · Started Nov 7, 2022 · Posted by FDA Jan 19, 2023
Reason given: For one lot of CBC-3D Hematology Control, the Normal Level may exhibit hemolysis or deterioration due to microbial contamination.
Cause as FDA categorized it: Under Investigation by firm
Primus Corporation dba Trinity Biotech
Z-0349-2023 · Started Oct 5, 2021 · Posted by FDA Dec 1, 2022
Reason given: The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. The unacceptable Control Level 1 value results in the Analyzer generating an error code which stops further testing and nullifies associated patient samples, resulting in a delay...
Cause as FDA categorized it: Nonconforming Material/Component
Primus Corporation dba Trinity Biotech
Z-0350-2023 · Started Oct 5, 2021 · Posted by FDA Dec 1, 2022
Reason given: The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. Additionally, per the firm, the unacceptable Control Level 1 value results in the Analyzer generating an error code which stops further testing and nullifies associated patient...
Cause as FDA categorized it: Nonconforming Material/Component
13 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.